The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting Poster, November 9, 2019 A Novel TNFRSF25 Agonist, PTX35, Synergizes with Gp96-Ig/OX40L-Ig to Enhance Effector and Memory Anti-Tumor CD8+ T Cell Responses and Delay Tumor Growth
The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting Poster, November 8, 2019 Preclinical Development of a Novel TNFRSF25 Agonist Antibody, PTX-35, for Cancer Immunotherapy Combinations
The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting Poster, November 8, 2019 Preclinical Development of a Novel, Allogeneic, OX40L-Secreting, Therapeutic Cancer Vaccine for use in Combination with a gp96-Secreting Vaccine for Solid Tumors
The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting Poster, November 8, 2019; Treating Advanced Non-Small Lung Cancer (NSCLC) Patients After Checkpoint Inhibitor Treatment Failure With a Novel Combination of Viagenpumatucel-L (HS-110) Plus Nivolumab
